JAK inhibitors Transcript

JAK inhibitors Transcript

So, we've been working on this class of drugs [JAK inhibitors] now for about 5 or 6 years, both in our research laboratory and clinically. And we've uncovered a series of mechanisms that suggests that these drugs are going to be very active, probably not only in...

read more
What is Multiple Myeloma?

What is Multiple Myeloma?

Survival and treatments are improving for this type of blood cancer You don't expect to break a rib while doing light housekeeping. Similarly, you wouldn't think your worsening back pain might be caused by a type of blood cancer. However, these are among classic...

read more
Outcomes in Multiple Myeloma Patients Evaluated

Outcomes in Multiple Myeloma Patients Evaluated

There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264 individuals. Participants all had multiple myeloma with an initial visit occurring between 2004 and 2014. They had treatment at a clinic that...

read more
Advances in the Management of Multiple Myeloma

Advances in the Management of Multiple Myeloma

James R Berenson, MD, Tanya M Spektor, PhD, and James Wang Institute for Myeloma & Bone Cancer Research; James R Berenson, MD, Inc; and ONCOtherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is...

read more
KIIS Cares Interview

KIIS Cares Interview

What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the cells that make your blood, your red cells, your white cells, and your platelets. This plays a key role in maintaining the strength of the bone. Why: There have been several recent...

read more
Talking About Myeloma with Loved Ones

Talking About Myeloma with Loved Ones

Do you feel the Love? The New Year is here. Perhaps you have been newly diagnosed? Whether a Myeloma warrior, or new to the world of MM, talking about the disease with loved ones can be difficult, at best. What is Multiple Myeloma anyway? It’s hard enough to...

read more
Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy Garceau, IMBCR’s Marathon Team Captain

Tommy, who has been Dr. Berenson’s able assistant for many years, has a passion for athletics and training. In July 2013, he started Team IMBCR at a time when he was also participating in several marathons, half-marathons and trail running and half iron distance...

read more
ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma

Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy...

read more
Multiple Myeloma: ‘Old Rules’ No Longer Apply

Multiple Myeloma: ‘Old Rules’ No Longer Apply

Original Article Writen by: Robert Carlson - Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple myeloma have become plentiful in the past few years, with a panoply of options. Consequently, “the old rules no longer apply,” says James Berenson,...

read more
Counterpoints: To Transplant or Not To Transplant

Counterpoints: To Transplant or Not To Transplant

More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common primary malignancy of the bone marrow.1, The 5-year survival rate for MM patients has increased from 25% in 1975 to almost 40% due to newer and more...

read more
Tom Brokaw Bravely Facing Cancer Diagnosis

Tom Brokaw Bravely Facing Cancer Diagnosis

ORIGINAL STORY: Click Here. INSIDE EDITION: Airdate: 02/12/2014 There is an outpouring of support for legendary broadcaster Tom Brokaw as he bravely battles bone marrow cancer. Brokaw stepped down as anchor of the NBC Nightly News in 2004. He was diagnosed last August...

read more
NBC News Special Correspondent Tom Brokaw

NBC News Special Correspondent Tom Brokaw

In response to NBC News Special Correspondent Tom Brokaw’s announcement that he has been diagnosed with multiple myeloma, a rare blood cancer of malignant cells found in the bone marrow, leading physician Dr. James Berenson is encouraged that Mr. Brokaw is receiving...

read more
Is Treating Myeloma A Marathon or a Sprint?

Is Treating Myeloma A Marathon or a Sprint?

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, discusses the importance of weighing risks and benefits when choosing a myeloma treatment path.  Dr. Berenson also discusses why he feels that having a variety of current treatment options,...

read more
What’s New in Myeloma?

What’s New in Myeloma?

There have been several recent breakthroughs for the treatment of multiple myeloma patients that have led to new therapeutic options. With regards to newer agents, there are a number of new drugs in development.  The most promising are the antibody-based treatments...

read more
Dedication of “Determination”

Dedication of “Determination”

The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication of a newly designed artwork for IMBCR. Artist, Ted Kirby, named the artwork “Determination”, in honor of all those who are determined to cure Multiple Myeloma. Please...

read more